Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Vera, R; Gomez, ML; Ayuso, JR; Figueras, J; Garcia-Alfonso, P; Martinez, V; Lacasta, A; Ruiz-Casado, A; Safont, MJ; Aparicio, J; Campos, JM; Camara, JC; Martin-Richard, M; Montagut, C; Pericay, C; Vieitez, JM; Falco, E; Jorge, M; Marin, M; Salgado, M; Viudez, A.

Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study

Cancers. 2020; 12(8): Nº de citas: 10 [doi:10.3390/cancers12082259]

Carmona-Bayonas, A; Gomez, D; de Castro, EM; Segura, PP; Langa, JM; Jimenez-Fonseca, P; Canovas, MS; Moran, LO; Escobar, IG; Blanco, ABR; Perez, IF; de Prado, PM; Balanya, RPI; Verduguez, TQ; Rodriguez-Lescure, A; Munoz, A.

A snapshot of cancer-associated thromboembolic disease in 2018-2019: First data from the TESEO prospective registry

European Journal of Internal Medicine. 2020; 78: 41-49 Nº de citas: 33 [doi:10.1016/j.ejim.2020.05.031]

Camps Herrero, C; Batista, N; Diaz Fernandez, N; Escobar Alvarez, Y; Gonzalo Gomez, A; Isla Casado, D; Salud, A; Terrasa Pons, J; Guillem Porta, V.

Breakthrough cancer pain: review and calls to action to improve its management

Clinical & Translational Oncology. 2020; 22(8): 1216-1226 Nº de citas: 29 [doi:10.1007/s12094-019-02268-8]

Izquierdo, JAA; Lopez, IM; Morillo, PS; Rodas, IM; Cidoncha, EM.

Utility of PET/CT in patients with stage I-III melanoma

Clinical & Translational Oncology. 2020; 22(8): 1414-1417 Nº de citas: 8 [doi:10.1007/s12094-019-02252-2]

Galeano-Valle, F; Perez-Rus, G; Demelo-Rodriguez, P; Ordieres-Ortega, L; Ortega-Moran, L; Munoz-Martin, AJ; Medina-Molina, S; Alvarez-Sala-Walther, LA; del-Toro-Cervera, J.

Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin

Clinical & Translational Oncology. 2020; 22(8): 1312-1320 Nº de citas: 4 [doi:10.1007/s12094-019-02258-w]

Sanchis, AC; Gallego, J; Hernandez, R; Arrazubi, V; Custodio, A; Cano, JM; Aguado, G; Macias, I; Lopez, C; Lopez, F; Visa, L; Garrido, M; Lago, NM; Montes, AF; Limon, ML; Azkarate, A; Pimentel, P; Reguera, P; Ramchandani, A; Cacho, JD; Carnicero, AM; Granja, M; Richard, MM; Perez, CH; Hurtado, A; Serra, O; Buxo, E; Tocino, RV; Jimenez-Fonseca, P; Carmona-Bayonas, A.

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

PLoS One. 2020; 15(7): Nº de citas: 23 [doi:10.1371/journal.pone.0235848]

Amor-Garcia, MA; Collado-Borrell, R; Escudero-Vilaplana, V; Melgarejo-Ortuno, A; Herranz-Alonso, A; Arija, JAA; Sanjurjo-Saez, M.

Assessing Apps for Patients with Genitourinary Tumors Using the Mobile Application Rating Scale (MARS): Systematic Search in App Stores and Content Analysis

JMIR mHealth and uHealth. 2020; 8(7): Nº de citas: 40 [doi:10.2196/17609]

Wainberg, ZA; Feeney, K; Lee, MA; Munoz, A; Gracian, AC; Lonardi, S; Ryoo, BY; Hung, AN; Lin, Y; Bendell, J; Hecht, JR.

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

BMC CANCER. 2020; 20(1): Nº de citas: 29 [doi:10.1186/s12885-020-07110-x]

Segui, MA; Cruz, JJ; Alba, E; Feliu, J; Jara, C; Rivera, F; Lescure, AR; Lorenzo, A; Martin, M.

Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain

Clinical & Translational Oncology. 2020; 22(7): 1049-1058 [doi:10.1007/s12094-019-02230-8]

Onesti, CE; Rugo, HS; Generali, D; Peeters, M; Zaman, K; Wildiers, H; Harbeck, N; Martin, M; Cristofanilli, M; Cortes, J; Tjan-Heijnen, V; Hurvitz, SA; Berchem, G; Tagliamento, M; Campone, M; Bartsch, R; De Placido, S; Puglisi, F; Rottey, S; Muller, V; Ruhstaller, T; Machiels, JP; Conte, P; Awada, A; Jerusalem, G.

Oncological care organisation during COVID-19 outbreak

ESMO Open. 2020; 5(4): Nº de citas: 29 [doi:10.1136/esmoopen-2020-000853]

Garcia-Gonzalez, X; Kaczmarczyk, B; Abarca-Zabalia, J; Thomas, F; Garcia-Alfonso, P; Robles, L; Pachon, V; Vaz, A; Salvador-Martin, S; Sanjurjo-Saez, M; Lopez-Fernandez, LA.

New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2020; 86(1): 45-54 Nº de citas: 17 [doi:10.1007/s00280-020-04093-1]

Paz-Ares, L; Kim, TM; Vicente, D; Felip, E; Lee, DH; Lee, KH; Lin, CC; Flor, MJ; Di Nicola, M; Alvarez, RM; Dussault, I; Helwig, C; Ojalvo, LS; Gulley, JL; Cho, BC.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Journal of Thoracic Oncology. 2020; 15(7): 1210-1222 Nº de citas: 177 [doi:10.1016/j.jtho.2020.03.003]

Trilla-Fuertes, L; Ghanem, I; Maurel, J; G-Pastrian, L; Mendiola, M; Pena, C; Lopez-Vacas, R; Prado-Vazquez, G; Lopez-Camacho, E; Zapater-Moros, A; Heredia, V; Cuatrecasas, M; Garcia-Alfonso, P; Capdevila, J; Conill, C; Garcia-Carbonero, R; Heath, KE; Ramos-Ruiz, R; Llorens, C; Campos-Barros, A; Gamez-Pozo, A; Feliu, J; Vara, JAF.

Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma

Translational Oncology. 2020; 13(7): Nº de citas: 9 [doi:10.1016/j.tranon.2020.100778]

Bockorny, B; Semenisty, V; Macarulla, T; Borazanci, E; Wolpin, BM; Stemmer, SM; Golan, T; Geva, R; Borad, MJ; Pedersen, KS; Park, JO; Ramirez, RA; Abad, DG; Feliu, J; Munoz, A; Ponz-Sarvise, M; Peled, A; Lustig, TM; Bohana-Kashtan, O; Shaw, SM; Sorani, E; Chaney, M; Kadosh, S; Haras, AV; Von Hoff, DD; Hidalgo, M.

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

NATURE MEDICINE. 2020; 26(6): 878 Nº de citas: 464 [doi:10.1038/s41591-020-0880-x]

Jerez, Y; Herrero, B; Arregui, M; Moron, B; Martin, M; Echavarria, I.

Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer

Future Oncology. 2020; 16(17): 1165-1177 Nº de citas: 5 [doi:10.2217/fon-2020-0046]

Mayor, J; Alvarez-Maestro, M; Arranz, JA; Laguna, MP.

De-escalation: Testicular cancer

ARCHIVOS ESPANOLES DE UROLOGIA. 2020; 73(5): 390-394

Dijksterhuis WPM; Stroes, CI; Tan, WL; Ithimakin, S; Calles, A; van Oijen MGH; Verhoeven RHA; Barriuso, J; Oosting, SF; Ivankovic, DK; Furness AJS; Bozovic-Spasojevic, I; Gomez-Roca, C; van Laarhoven HWM.

From presentation to paper: Gender disparities in oncological research

INTERNATIONAL JOURNAL OF CANCER. 2020; 146(11): 3011-3021 Nº de citas: 14 [doi:10.1002/ijc.32660]

Galsky, MD; Arija, JAA; Bamias, A; Davis, ID; De Santis, M; Kikuchi, E; Garcia-del-Muro, X; De Giorgi, U; Mencinger, M; Izumi, K; Panni, S; Gumus, M; Ozguroglu, M; Kalebasty, AR; Park, SH; Alekseev, B; Schutz, FA; Li, JR; Ye, DW; Vogelzang, NJ; Bernhard, S; Tayama, D; Mariathasan, S; Mecke, A; Thastrom, A; Grande, E; IMvigor130 Study Grp.

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

LANCET. 2020; 395(10236): 1547-1557 Nº de citas: 663 [doi:10.1016/S0140-6736(20)30230-0]